JMM Correspondence
Use of a multiplexed immunoassay for detection of serotypespecific Streptococcus pneumoniae antigen in pleural fluid and cerebrospinal fluid specimens
We recently described a method for detection of Streptococcus pneumoniae serotypespecific antigens in urine (Sheppard et al., 2011) . Here, we report the use of this method for detection of serotype-specific antigen directly from cerebrospinal fluid (CSF) and pleural fluid samples. The use of non-culture-based methods for detection and typing of pneumococci in severe invasive disease cases such as meningitis and empyema is of great benefit since many of these specimens are culture-negative (Balfour-Lynn et al., 2005; Ceyhan et al., 2010) . PCR assays have been used in various studies for determining serotypes from isolates (Lawrence et al., 2003) and clinical samples (Morais et al., 2007; Tarragó et al., 2008) but these methods can be complicated and time-consuming to perform and do not give a direct detection of expressed polysaccharides.
Antigen detection using the BinaxNOW immunochromatographic kit [testing for C-polysaccharide (C-Ps)] has recently been shown to be useful for detecting pneumococci in pleural effusions (Casado Flores et al., 2010) and was already validated for use in CSF (Samra et al., 2003) . However, this method, whilst useful for primary diagnosis, gives no serotype information, which is a pre-requisite for national surveillance of serious pneumococcal infections and is essential for ascertaining vaccine effectiveness in individual vaccinees.
The use of an ELISA method for serotypespecific antigen detection on pleural fluid samples was reported some time ago (Eltringham et al., 2003) . This study showed that the majority of the samples tested were of serotype 1, but the method has not been routinely used due to the large sample volume and considerable reagent requirement for multiple serotype detection using such ELISA methods. The development of our multiplex immunoassay reduces both the complexity and large sample volume requirement for serotype-specific antigen detection and it is therefore applicable to samples with limited volume, especially those which are inherently difficult to obtain in large volume, such as CSF. We describe in this correspondence the use of the previously described multiplex immunoassay, which detects 14 serotypes/groups, on both pleural effusion and CSF samples for detection of serotypes/groups 1, 3, 4, 5, 6A/C, 6B, 7F/A, 8, 9V, 14, 18, 19A, 19F, The assay was performed as previously described (Sheppard et al., 2011) ; the only deviation was the processing of the CSF and pleural fluid samples prior to testing. To render the samples safe and suitable for testing, the samples were processed in the following way.
CSF samples were diluted 1 : 3 in sterile PBS (HPA media services) to provide an appropriate volume for processing. Proteinase K (Qiagen) was added at a concentration of 30 mAU ml 21 , i.e. 10 ml neat solution in 200 ml diluted CSF or neat pleural fluid sample. The samples were incubated at 56 u C for 10 min on a heating block (Grant) and then transferred to a second heating block set at 95 u C for 30 min to inactivate the proteinase K and any potential pathogens. The samples were then centrifuged at 16 000 g for 2 min. Digested CSF supernatant was removed to a fresh tube, and an aliquot of the digested pleural fluid sample was diluted in PBS to achieve a final 1 : 5 dilution, ready for testing. Depending on the sample size, up to 100 ml per well of the processed sample was tested in the assay as described previously (Sheppard et al., 2011) .
Samples for testing
Since September 2006, the Respiratory and Systemic Infection Laboratory (RSIL) has been testing S. pneumoniae PCR-positive CSF and pleural/empyema fluids received from collaborators at the HPA Meningococcal Reference Unit (Manchester) and Great Ormond Street Hospital (London) in the multiplex immunoassay. The samples were tested at the originating laboratory by specific autolysin PCR assay Harris et al., 2008) and those received from Manchester HPA were also positive by pneumolysin PCR (Corless et al., 2001) . This is part of enhanced surveillance activities aimed at improving information regarding serotype distributions in these, often culture-negative, cases. The serotype result of any matching culture isolates obtained from the patients was only seen when the results of the non-culture assay were added to the laboratory information management system (LIMS). Therefore, the tests were done blinded to any previously obtained serotype results.
In the first 3 years of this enhanced surveillance activity, 323 pneumococcal PCR-positive CSF samples from 300 patients of all ages (33 % below age 17, range 0-86 years) and 223 pneumococcal PCR-positive pleural/empyema fluid samples from 214 children up to the age of 16 were received from the sending centres, who were asked to send all S. pneumoniae PCR-positives on for testing in the multiplex assay. All samples received at RSIL are included in this analysis. Retrospective review of LIMS data revealed that serotype data from S. pneumoniae isolates were only obtained from 79 (26 %) of the patients from whom a CSF sample was received and 8 (4 %) of the patients from whom a pleural fluid sample was received.
Results obtained from the samples
Serotypes were determined directly from 176 CSF samples (54 %), and an additional 79 (24 %) were positive for pneumococcal C-Ps only. In total, 139 of the 300 and were negative for serotype in the assay. Therefore, the sensitivity for assay types was 97 % for CSF samples and 100 % for pleural fluid samples against culture. Specificity was 100 % for both sample types against culture.
In general, the very high signal strengths obtained from the pleural fluid specimens suggested an abundance of polysaccharide present in the samples (the results were indicative of .50 ng polysaccharide ml 21 in many cases). In comparison, the strengths of the signals from CSF samples tended to vary more greatly in concentration from sample to sample but with many ,0.5 ng ml 21 . There was a noticeably different distribution of serotypes present in the pleural fluid specimens compared to the CSF specimens, with serotypes 1 and 3 being the predominant serotypes in pleural fluid specimens, supporting the findings of previous studies (Tarragó et al., 2008) , and a much more diverse range of serotypes present in the CSF specimens, which was more similar to the overall distribution of serotypes from all age groups seen in the culture data (Table 1 ).
The samples positive only for the C-Ps suggest the presence of serotypes not detectable in the assay. Some of the PCR-positive specimens were completely negative in the assay. There were more negative results from the CSF samples where the overall signal strengths of the positive samples were much lower; this may be due to very small amounts of bacteria present and in some cases very small amounts of sample (,5 ml) available to test. Negative results may also be due to sensitivity issues with the C-Ps assay, as discussed in the original paper, where it was found that not all samples, even when positive for a serotype, were also positive for C-Ps. False-positives in the PCR assays are another possible source of the negative results, although this is unlikely due to the targets selected for PCR testing.
Conclusions
The use of the previously described multiplex immunoassay on CSF and pleural fluid samples has been shown to be a valuable source of serotype information for enhanced surveillance activities and conjugate vaccine effectiveness estimates which would otherwise not be available. The assay performs particularly well on pleural fluid samples, partly due to the distribution of serotypes (more of those available in the assay) and partly due to the large amount of polysaccharide detectable in these specimens. 
